168151-99-3Relevant articles and documents
Monodisperse nickel-nanoparticles for stereo- and chemoselective hydrogenation of alkynes to alkenes
Murugesan, Kathiravan,Alshammari, Ahmad S.,Sohail, Manzar,Beller, Matthias,Jagadeesh, Rajenahally V.
, p. 372 - 377 (2019)
Here, we report the use of monosaccharides for the preparation of novel nickel nanoparticles (NP), which constitute selective hydrogenation catalysts. For example, immobilization of fructose and Ni(OAc)2 on silica and subsequent pyrolysis under inert atmosphere produced graphitic shells encapsulated Ni-NP with uniform size and distribution. Interestingly, fructose acts as structure controlling compound to generate specific graphitic layers and the formation of monodisperse NP. The resulting stable and reusable catalysts allow for stereo- and chemoselective semihydrogenation of functionalized and structurally diverse alkynes in high yields and selectivity.
Nickel-Catalyzed Stereodivergent Synthesis of E- and Z-Alkenes by Hydrogenation of Alkynes
Murugesan, Kathiravan,Bheeter, Charles Beromeo,Linnebank, Pim R.,Spannenberg, Anke,Reek, Joost N. H.,Jagadeesh, Rajenahally V.,Beller, Matthias
, p. 3363 - 3369 (2019/06/28)
A convenient protocol for stereodivergent hydrogenation of alkynes to E- and Z-alkenes by using nickel catalysts was developed. Simple Ni(NO3)2?6 H2O as a catalyst precursor formed active nanoparticles, which were effective for the semihydrogenation of several alkynes with high selectivity for the Z-alkene (Z/E>99:1). Upon addition of specific multidentate ligands (triphos, tetraphos), the resulting molecular catalysts were highly selective for the E-alkene products (E/Z>99:1). Mechanistic studies revealed that the Z-alkene-selective catalyst was heterogeneous whereas the E-alkene-selective catalyst was homogeneous. In the latter case, the alkyne was first hydrogenated to a Z-alkene, which was subsequently isomerized to the E-alkene. This proposal was supported by density functional theory calculations. This synthetic methodology was shown to be generally applicable in >40 examples and scalable to multigram-scale experiments.
Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl- 3-hydroxy. N-[3'-methyl-4'-(trifluoromethyl)phenyl]propenamide and related compounds
Kuo, Elizabeth A.,Hambleton, Philip T.,Kay, David P.,Evans, Phillip L.,Matharu, Saroop S.,Little, Edward,McDowall, Neil,Jones, C. Beth,Hedgecock, Charles J. R.,Yea, Christopher M.,Chan, A. W. Edith,Hairsine, Peter W.,Ager, Ian R.,Tully, W. Roger,Williamson, Richard A.,Westwood, Robert
, p. 4608 - 4621 (2007/10/03)
The active metabolite (2) of the novel immunosuppressive agent leflunomide (1) has been shown to inhibit the enzyme dihydroorotate dehydrogenase (DHODH). This enzyme catalyzes the fourth step in de novo pyrimidine biosynthesis. A series of analogues of the active metabolite 2 have been synthesized. Their in vivo biological activity determined in rat and mouse delayed type hypersensitivity has been found to correlate well with their in vitro DHODH potency. The most promising compound (3) has shown activity in rat and mouse collagen (II)-induced arthritis models (ED50 = 2 and 31 mg/kg, respectively) and has shown a shorter half-life in man when compared with leflunomide. Clinical studies in rheumatoid arthritis are in progress.
